<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2014-3-10-16</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-430</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Optimal duration of therapy in the recovery period of vestibular diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Оптимальная длительность терапии в восстановительном периоде вестибулярных заболеваний</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Замерград</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zamergrad</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, Россия 119435, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991</p></bio><email xlink:type="simple">zamergrad@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Парфенов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Parfenov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, Россия 119435, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яхно</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakhno</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва, Россия 119435, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Клиника нервных болезней им. А.Я. Кожевникова ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.Ya. Kozhevnikov Clinic of Nervous System Diseases, I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>10</month><year>2014</year></pub-date><volume>6</volume><issue>3</issue><fpage>10</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Zamergrad M.V., Parfenov V.A., Yakhno N.N., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Замерград М.В., Парфенов В.А., Яхно Н.Н.</copyright-holder><copyright-holder xml:lang="en">Zamergrad M.V., Parfenov V.A., Yakhno N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/430">https://nnp.ima-press.net/nnp/article/view/430</self-uri><abstract><p>Dizziness is a common symptom in neurological and general medical practice. In most cases it is caused by diseases of the central or peripheral vestibular system. The most common vestibular system diseases include benign paroxysmal postural vertigo, dizziness, Meniere's disease, vestibular neuronitis, and cerebrovascular diseases. One of the main treatments for the diseases accompanied by dizziness is vestibular rehabilitation that is a complex of exercises, the goal of which is to stimulate vestibular compensation. Adequate vestibular compensation allows a patient to get rid of dizziness and unsteadiness even though vestibular system injury is irreversible. Some medications are able to enhance the efficiency of vestibular rehabilitation. At the same time, the optimal duration of treatment for the most common vestibular disorders has not beenadequately explored. The paper gives the results of an observational program, whose purpose was to determine the optimal duration of vestibular rehabilitation in combination with the use of tanakan in patients with non-progressive unilateral peripheral vestibular disorder.</p><sec><title>Patients and methods</title><p>Patients and methods. Data on 46 patients aged 19 to 70 years who underwent vestibular rehabilitation and took tanakan for vertigo caused by vestibular neuronitis (n = 44), labyrinthitis (n =1), or Ramsay Hunt syndrome (n = 1) were analyzed. All the patients were examined four times. The symptoms were recorded and the histories of disease were considered. The degree of vestibular disorders, including vertigo, was assessed when collecting complaints. The symptoms of vertigo were objectivized using its vertigo rating scale and five-point subjective rating scale for vertigo. All the patients underwent standard somatic and neurological examinations and videonystagmography. During the first visit after diagnosis, vestibular exercises were chosen for the patients and tanakan was used in a dose of 40 mg thrice daily to accelerate vestibularcompensation. During visits 2, 3, and 4, the symptoms of the disease were recorded in the patients and the time course of treatment-induced changes in their status was estimated.</p></sec><sec><title>Results</title><p>Results. The optimal duration of treatment was established to be at least 2 months. Vestibular exercises in combination with the intake of tanakan resulted in a reduction in the symptoms of vestibular dysfunction and in emotional improvement in the patients.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Головокружение – частый симптом в неврологической и общей медицинской практике. В большинстве случаев головокружение бывает обусловлено заболеваниями центрального или периферического отдела вестибулярной системы. Среди наиболее распространенных заболеваний вестибулярной системы – доброкачественное пароксизмальное позиционное головокружение, болезнь Меньера, вестибулярный нейронит и цереброваскулярные заболевания. Одним из основных методов лечения заболеваний, сопровождающихся головокружением, является вестибулярная реабилитация – комплекс упражнений, цель которых состоит в стимуляции вестибулярной компенсации. Полноценная вестибулярная компенсация позволяет больному избавиться от головокружения и неустойчивости даже в тех случаях, когда повреждение вестибулярной системы оказывается необратимым. Некоторые лекарственные средства способны повысить эффективность вестибулярной реабилитации. При этом оптимальная продолжительность лечения при наиболее распространенных вестибулярных расстройствах недостаточно изучена. В статье представлены результаты наблюдательной программы, целью которой было определение оптимальной продолжительности вестибулярной реабилитации в сочетании с приемом танакана у пациентов с односторонним непрогрессирующим периферическим вестибулярным расстройством.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Проанализировано 46 пациентов в возрасте от 19 до 70 лет, проходящих вестибулярную реабилитацию и принимающих танакан в связи с головокружением, обусловленным вестибулярным нейронитом (n=44), лабиринтитом (n=1) и синдромом Рамсея Ханта (n=1). Все пациенты были осмотрены четыре раза. Регистрировались симптомы и анамнез заболевания. При сборе жалоб оценивалась выраженность вестибулярных нарушений, в том числе головокружения. Объективизация симптомов головокружения осуществлялась с помощью Шкалы оценки головокружения (ШОГ) и 5-балльной Шкалы субъективной оценки выраженности головокружения. Всем пациентам проводилось стандартное соматическое и неврологическое исследование, выполнялась видеонистагмография. Во время первого визита после установления диагноза пациентам подбиралась ве-стибулярная гимнастика, а для ускорения вестибулярной компенсации назначался танакан в дозе 40 мг 3 раза в сутки. При втором, третьем и четвертом визитах снова регистрировались симптомы заболевания, а также оценивалась динамика состояния пациента на фоне лечения.</p></sec><sec><title>Результаты исследования</title><p>Результаты исследования. Установлено, что оптимальная продолжительность лечения составляет не менее 2 мес. Сочетание вестибулярной гимнастики с приемом танакана приводило к уменьшению симптомов вестибулярной дисфункции, а также улучшению эмоционального состояния пациентов.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>головокружение</kwd><kwd>вестибулярный нейронит</kwd><kwd>вестибулярная реабилитация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>dizziness</kwd><kwd>vestibular neuronitis</kwd><kwd>vestibular rehabilitation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">«Ипсен Фарма»</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Neuhauser HK. Epidemiology of vestibular vertigo. Neurology. 2005;65:898–904. DOI: http://dx.doi.org/10.1212/01.wnl. 0000175987.59991.3d.</mixed-citation><mixed-citation xml:lang="en">Neuhauser HK. Epidemiology of vestibular vertigo. Neurology. 2005;65:898–904. DOI: http://dx.doi.org/10.1212/01.wnl. 0000175987.59991.3d.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Замерград МВ, Парфенов ВА, Яхно НН и др. Диагностика системного головокружения в амбулаторной практике. Неврологический журнал. 2014;19(2):23–9. [Zamergrad MV, Parfenov VA, Yakhno NN, et al. The diagnosis of systemic vertigo in out-patient practice. Nevrologicheskii zhurnal. 2014;19(2):23–9. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Замерград МВ, Парфенов ВА, Яхно НН и др. Диагностика системного головокружения в амбулаторной практике. Неврологический журнал. 2014;19(2):23–9. [Zamergrad MV, Parfenov VA, Yakhno NN, et al. The diagnosis of systemic vertigo in out-patient practice. Nevrologicheskii zhurnal. 2014;19(2):23–9. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Balci BD, Akdal G, Yaka E, Angin S. Vestibular rehabilitation in acute central vestibulopathy: a randomized controlled trial. J Vestib Res. 2013;23(4–5):259–67.</mixed-citation><mixed-citation xml:lang="en">Balci BD, Akdal G, Yaka E, Angin S. Vestibular rehabilitation in acute central vestibulopathy: a randomized controlled trial. J Vestib Res. 2013;23(4–5):259–67.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hillier SL, Hollohan V. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2007;17: CD005397.</mixed-citation><mixed-citation xml:lang="en">Hillier SL, Hollohan V. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev. 2007;17: CD005397.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Han BI, Song HS, Kim JS. Vestibular rehabilitation therapy: review of indications, mechanisms, and key exercises. J Clin Neurol. 2011 Dec;7(4):184–96. DOI: http://dx.doi.org/10.3988/jcn.2011.7.4.184.</mixed-citation><mixed-citation xml:lang="en">Han BI, Song HS, Kim JS. Vestibular rehabilitation therapy: review of indications, mechanisms, and key exercises. J Clin Neurol. 2011 Dec;7(4):184–96. DOI: http://dx.doi.org/10.3988/jcn.2011.7.4.184.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shepard NT, Telian SA. Programmatic vestibular rehabilitation. Otolaryngol Head Neck Surg. 1995;112:173–82. DOI: http://dx.doi.org/10.1016/S0194- 5998(95)70317-9.</mixed-citation><mixed-citation xml:lang="en">Shepard NT, Telian SA. Programmatic vestibular rehabilitation. Otolaryngol Head Neck Surg. 1995;112:173–82. DOI: http://dx.doi.org/10.1016/S0194- 5998(95)70317-9.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Denise P, Bustany P. The effect of extract of Ginkgo biloba (EGb 761) on central compensation of a total unilateral peripheral vestibular deficite in the rat. In: Vestibular compensation: facts, theories and clinical perspectives. Lacour M, Toupet M, Denise P, Chirsten Y, editors. Paris: Elsevier; 1989. P. 201–8.</mixed-citation><mixed-citation xml:lang="en">Denise P, Bustany P. The effect of extract of Ginkgo biloba (EGb 761) on central compensation of a total unilateral peripheral vestibular deficite in the rat. In: Vestibular compensation: facts, theories and clinical perspectives. Lacour M, Toupet M, Denise P, Chirsten Y, editors. Paris: Elsevier; 1989. P. 201–8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lacour M, Ez-Zaher L, Raymond J. Plasticity mechanisms in vestibular compensation in the cat are improved by an extract of Ginkgo biloba (EGb 761). Pharmacol Biochem Behav. 1991 Oct;40(2):367–79. DOI: http://dx.doi.org/10.1016/0091-3057(91)90568-M.</mixed-citation><mixed-citation xml:lang="en">Lacour M, Ez-Zaher L, Raymond J. Plasticity mechanisms in vestibular compensation in the cat are improved by an extract of Ginkgo biloba (EGb 761). Pharmacol Biochem Behav. 1991 Oct;40(2):367–79. DOI: http://dx.doi.org/10.1016/0091-3057(91)90568-M.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yabe T, Chat M, Malherbe E, Vidal PP. Effects of Ginkgo biloba extract (EGb 761) on the guinea pig vestibular system. Pharmacol Biochem Behav. 1992;42(4):595–604. DOI: http://dx.doi.org/10.1016/0091-3057(92)90004-Y.</mixed-citation><mixed-citation xml:lang="en">Yabe T, Chat M, Malherbe E, Vidal PP. Effects of Ginkgo biloba extract (EGb 761) on the guinea pig vestibular system. Pharmacol Biochem Behav. 1992;42(4):595–604. DOI: http://dx.doi.org/10.1016/0091-3057(92)90004-Y.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Maclennan K, Smith PF, Darlington CL. The effects of ginkgolide B (BN52021) on guinea pig vestibular nucleus neurons in vitro: importance of controlling for effects of dimethylsulphoxide (DMSO) vehicles. Neurosci Res. 1996;26(4):395–9. DOI: http://dx.doi.org/10.1016/S0168- 0102(96)01118-2.</mixed-citation><mixed-citation xml:lang="en">Maclennan K, Smith PF, Darlington CL. The effects of ginkgolide B (BN52021) on guinea pig vestibular nucleus neurons in vitro: importance of controlling for effects of dimethylsulphoxide (DMSO) vehicles. Neurosci Res. 1996;26(4):395–9. DOI: http://dx.doi.org/10.1016/S0168- 0102(96)01118-2.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hamann KF. Physical treatment of vertigo of peripheral origin in combination with standargized ginkgo biloba extract (EGb 761). Therapiewoche. 1985;33:4586–90.</mixed-citation><mixed-citation xml:lang="en">Hamann KF. Physical treatment of vertigo of peripheral origin in combination with standargized ginkgo biloba extract (EGb 761). Therapiewoche. 1985;33:4586–90.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hamann KF. Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO. 2007;55(4):258–63. DOI: http://dx.doi.org/10.1007/s00106-006-1440-5.</mixed-citation><mixed-citation xml:lang="en">Hamann KF. Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO. 2007;55(4):258–63. DOI: http://dx.doi.org/10.1007/s00106-006-1440-5.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Haguenauer JP, Cantenot F, Koskas H, Pierart H. Treatment of equilibrium disorders with Ginkgo biloba extract. A multicenter double- blind drug vs. placebo study. Presse Med. 1986;15(31):1569–72.</mixed-citation><mixed-citation xml:lang="en">Haguenauer JP, Cantenot F, Koskas H, Pierart H. Treatment of equilibrium disorders with Ginkgo biloba extract. A multicenter double- blind drug vs. placebo study. Presse Med. 1986;15(31):1569–72.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Claussen CF, Kirtane MV. Randomisierte doppelblindstudie zur wirkung von extractum Ginkgo biloba bei Schwindel und Gangunsicherheit des alteren Menschen. In: Presyvertigo, Presbyataxie, Presbytinnitus. Claussen CF, editor. Berlin: Springer; 1985. P. 103–15. DOI: http://dx.doi.org/10.1007/978-3-642-70035-4_4.</mixed-citation><mixed-citation xml:lang="en">Claussen CF, Kirtane MV. Randomisierte doppelblindstudie zur wirkung von extractum Ginkgo biloba bei Schwindel und Gangunsicherheit des alteren Menschen. In: Presyvertigo, Presbyataxie, Presbytinnitus. Claussen CF, editor. Berlin: Springer; 1985. P. 103–15. DOI: http://dx.doi.org/10.1007/978-3-642-70035-4_4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg.1990;116:424–7. DOI: http://dx.doi.org/10.1001/archotol. 1990.01870040046011.</mixed-citation><mixed-citation xml:lang="en">Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg.1990;116:424–7. DOI: http://dx.doi.org/10.1001/archotol. 1990.01870040046011.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arbusow V, Schulz P, Strupp M, et al. Distribution of herpes simplex virus type I in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol. 1999;46:416–19. DOI: http://dx.doi.org/10.1002/1531- 8249(199909)46:3%3C416::AIDANA20% 3E3.0.CO;2-W.</mixed-citation><mixed-citation xml:lang="en">Arbusow V, Schulz P, Strupp M, et al. Distribution of herpes simplex virus type I in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol. 1999;46:416–19. DOI: http://dx.doi.org/10.1002/1531- 8249(199909)46:3%3C416::AIDANA20% 3E3.0.CO;2-W.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Okinaka Y, Sekitani T, Okazaki H, et al Progress of caloric response of vestibular neuronitis. Acta Otolaryngol. 1993;503:18–22. DOI: http://dx.doi.org/10.3109/ 00016489309128064.</mixed-citation><mixed-citation xml:lang="en">Okinaka Y, Sekitani T, Okazaki H, et al Progress of caloric response of vestibular neuronitis. Acta Otolaryngol. 1993;503:18–22. DOI: http://dx.doi.org/10.3109/ 00016489309128064.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, doubleblind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472–80. DOI: http://dx.doi.org/10.1016/j.jpschires. 2006.05.004.</mixed-citation><mixed-citation xml:lang="en">Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, doubleblind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472–80. DOI: http://dx.doi.org/10.1016/j.jpschires. 2006.05.004.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yang YL, Su YW, Ng MC, et al. Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated tartle. Neuropsychopharmacology. 2007;32(2):332–42. DOI: http://dx.doi.org/10.1038/sj.npp.1301060.</mixed-citation><mixed-citation xml:lang="en">Yang YL, Su YW, Ng MC, et al. Extract of Ginkgo biloba EGb761 facilitates extinction of conditioned fear measured by fear-potentiated tartle. Neuropsychopharmacology. 2007;32(2):332–42. DOI: http://dx.doi.org/10.1038/sj.npp.1301060.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng Y, Goddard M, Darlington CL, Smith PF. Effects of bilateral vestibular deafferentation on anxiety-related behaviours in Wistar rats. Behav Brain Res. 2008;193(1):55–62. DOI: http://dx.doi.org/10.1016/j.bbr.2008.04.018.</mixed-citation><mixed-citation xml:lang="en">Zheng Y, Goddard M, Darlington CL, Smith PF. Effects of bilateral vestibular deafferentation on anxiety-related behaviours in Wistar rats. Behav Brain Res. 2008;193(1):55–62. DOI: http://dx.doi.org/10.1016/j.bbr.2008.04.018.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Staab JP. Chronic dizziness: the interface between psychiatry and neuro-otology. Curr Opin Neurol. 2006;19(1):41–8. DOI: http://dx.doi.org/10.1097/01.wco.0000198102.95294.1f.</mixed-citation><mixed-citation xml:lang="en">Staab JP. Chronic dizziness: the interface between psychiatry and neuro-otology. Curr Opin Neurol. 2006;19(1):41–8. DOI: http://dx.doi.org/10.1097/01.wco.0000198102.95294.1f.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Staab JP, Ruckenstein MJ. Which comes first? Psychogenic dizziness versus otogenic anxiety. Laryngoscope. 2003;113(10):1714–8. DOI: http://dx.doi.org/10.1097/00005537- 200310000-00010.</mixed-citation><mixed-citation xml:lang="en">Staab JP, Ruckenstein MJ. Which comes first? Psychogenic dizziness versus otogenic anxiety. Laryngoscope. 2003;113(10):1714–8. DOI: http://dx.doi.org/10.1097/00005537- 200310000-00010.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
